J. Jolivet, K. H. Cowan, G. A. Curt, N. J. Clendeninn, and B. A. Chabner, The pharmacology and clinical use of methotrexate, New England Journal of Medicine, vol.309, issue.18, pp.1094-104, 1983.

. Méthotrexate,

E. Jaspard, Métabolisme des bases puriques, bases pyrimidiques et nucléotides

K. Schmiegelow, Advances in individual prediction of methotrexate toxicity: a review, British Journal of Haematology. sept, vol.146, issue.5, pp.489-503, 2009.

P. Treon and B. A. Chabner, Concepts in use of high-dose methotrexate therapy, Clinical Chemistry, vol.42, issue.8, pp.1322-1331, 1996.

B. A. Chabner and R. C. Young, Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target Tissues, Journal of Clinical Investigation. 1 août, vol.52, issue.8, pp.1804-1815, 1973.

H. Blasco, Facteurs pharmacocinétiques et variabilité de réponse aux médicaments utilisés dans le traitement des lymphomes, 2008.

G. Institut and . Roussy, , 2006.

C. Grommes, J. L. Rubenstein, L. M. Deangelis, A. Ferreri, and T. T. Batchelor, Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma, Neuro-Oncology. 19 févr, vol.21, issue.3, pp.296-305, 2019.

M. Joerger, A. Huitema, G. Illerhaus, and A. Ferreri, Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma, Leukemia & Lymphoma, vol.53, issue.10, pp.1867-75, 2012.

C. H. Han and T. T. Batchelor, Diagnosis and management of primary central nervous system lymphoma: Primary CNS Lymphoma. Cancer, vol.123, pp.4314-4338, 2017.

N. Goldschmidt, N. A. Horowitz, V. Hefetz, F. Darawshy, T. Mashiach et al., Addition of highdose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse, Leukemia & Lymphoma. 28 janv, pp.1-9, 2019.

G. Institut and . Roussy, Protocole LMBA02, Group for Research on Adult Acute Lymphoblastic Leukemia. Protocole GRAALL, vol.17, 2004.

, European Working Group on Adult Lymphoblastic Leukemia. Protocole

S. N. Reiss, L. W. Buie, A. N. Goldman, D. A. Devlin, S. M. Douer et al., Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia, Annals of Hematology. déc, vol.95, issue.12, pp.2009-2024, 2016.

W. E. Evans, P. R. Hutson, C. F. Stewart, D. A. Cairnes, W. P. Bowman et al., Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion, Clinical Pharmacology and Therapeutics. mars, vol.33, issue.3, pp.301-308, 1983.

P. C. Nathan, T. Whitcomb, P. L. Wolters, S. M. Steinberg, F. M. Balis et al., Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P, Leukemia & Lymphoma. janv, vol.47, issue.12, pp.2488-504, 2006.

K. Csordas, M. Hegyi, O. T. Eipel, J. Muller, D. J. Erdelyi et al., Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia: AntiCancer Drugs, févr, vol.24, issue.2, pp.189-97, 2013.

J. Li and P. Gwilt, The effect of malignant effusions on methotrexate disposition, Cancer Chemotherapy and Pharmacology, vol.50, issue.5, pp.373-82, 2002.

B. A. Chabner, C. J. Allegra, G. A. Curt, N. J. Clendeninn, J. Baram et al., Polyglutamation of methotrexate. Is methotrexate a prodrug, Journal of Clinical Investigation. 1 sept, vol.76, issue.3, pp.907-919, 1985.

S. P. Ackland and R. L. Schilsky, High-dose methotrexate: a critical reappraisal, Journal of Clinical Oncology. déc, vol.5, issue.12, pp.2017-2048, 1987.

E. Mantadakis, P. D. Cole, and B. A. Kamen, High-Dose Methotrexate in Acute Lymphoblastic Leukemia: Where Is the Evidence for Its Continued Use?, Pharmacotherapy. mai, vol.25, issue.5, pp.748-55, 2005.

B. C. Widemann and P. C. Adamson, Understanding and Managing Methotrexate Nephrotoxicity, The Oncologist. 1 juin, vol.11, issue.6, pp.694-703, 2006.

N. Pallet and . Physiologie-rénale,

A. S. Levey, A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation, Annals of Internal Medicine. 16 mars, vol.130, issue.6, pp.461-70, 1999.

A. S. Levey, L. A. Stevens, C. H. Schmid, A. Iii, H. I. Feldman et al., A New Equation to Estimate Glomerular Filtration Rate, Annals of Internal Medicine. 5 mai, vol.150, issue.9, pp.604-616, 2009.

W. E. Evans, C. F. Stewart, C. Chen, W. R. Crom, W. P. Bowman et al., Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. The Lancet, vol.18, pp.359-62, 1984.

W. E. Evans, W. R. Crom, M. Abromowitch, R. Dodge, A. T. Look et al., Clinical pharmacodynamics of high-dose methotrexate in Acute Lymphocytic Leukemia, New England Journal of Medicine. 20 févr, vol.314, issue.8, pp.471-478, 1986.

M. Takeda, S. Khamdang, S. Narikawa, H. Kimura, M. Hosoyamada et al., Characterization of Methotrexate Transport and Its Drug Interactions with Human Organic Anion Transporters, Journal of Pharmacology and Experimental Therapeutics. 1 août, vol.302, issue.2, pp.666-71, 2002.

Z. Chen, K. Lee, S. Walther, R. B. Raftogianis, M. Kuwano et al., Analysis of Methotrexate and Folate Transport by Multidrug Resistance Protein 4 (ABCC4), Cancer Research. 1 juin, vol.62, pp.3144-50, 2002.

T. Rau, B. Erney, R. Gores, T. Eschenhagen, J. Beck et al., High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations, Clinical Pharmacology & Therapeutics. nov, vol.80, issue.5, pp.468-76, 2006.

H. Garcia, V. Leblond, F. Goldwasser, D. Bouscary, E. Raffoux et al., Toxicité rénale du méthotrexate à haute dose, Néphrologie & Thérapeutique. avr, vol.14, pp.103-116, 2018.

D. W. Faltaos, J. S. Hulot, S. Urien, V. Morel, G. Kaloshi et al., Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy, Cancer Chemotherapy and Pharmacology, vol.58, issue.5, pp.626-659, 2006.

C. Dupuis, C. Mercier, C. Yang, S. Monjanel-mouterde, J. Ciccolini et al., High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy: Anti-Cancer Drugs, mars, vol.19, issue.3, pp.267-73, 2008.

G. Lui, J. Treluyer, B. Fresneau, S. Piperno-neumann, G. N. Corradini et al., A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial, The Journal of Clinical Pharmacology, issue.23, 2018.

D. Sur,

S. Mei, X. Li, X. Jiang, K. Yu, S. Lin et al., Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma, Journal of Pharmaceutical Sciences. mai, vol.107, issue.5, pp.1454-60, 2018.

K. H. Hui, H. M. Chu, P. S. Fong, W. Cheng, and T. N. Lam, Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma, The Journal of Clinical Pharmacology. 17 déc, pp.1-12, 2018.

M. Joerger, H. Bongard, . Van-den, P. Baas, J. H. Schornagel et al., Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients, British Journal of Clinical Pharmacology. juill, vol.62, issue.1, pp.71-80, 2006.

S. Bezabeh, A. C. Mackey, P. Kluetz, D. Jappar, and J. Korvick, Accumulating Evidence for a Drug-Drug Interaction Between Methotrexate and Proton Pump Inhibitors, The Oncologist. 1 avr, vol.17, issue.4, pp.550-554, 2012.

J. L. Gowarty, I. J. Patel, and J. D. Herrington, Altered methotrexate clearance in the treatment of CNS lymphoma with concurrent use of nitrofurantoin for a urinary tract infection, Journal of Oncology Pharmacy Practice, vol.0, issue.0, pp.1-4, 2018.

S. Reutenauer, D. Chauveau, and C. Récher, Surdosage au méthotrexate : complications, prise en charge et prévention. Réanimation, vol.18, pp.654-662, 2009.

D. E. Gerber, S. A. Grossman, T. Batchelor, and X. Ye, Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma, Cancer Chemotherapy and Pharmacology. 19 mars, vol.59, issue.6, pp.817-840, 2007.

J. N. Barreto, A. L. Mcclanahan, A. D. Rule, C. A. Thompson, and E. Frazee, Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function, Case Reports in Hematology, vol.2018, pp.1-5, 2018.

J. Borsi, D. Schuler, and P. Moe, Methotrexate administered by 6-h and 24-h infusion : a pharmacokinetic comparison, Cancer Chemotherapy and Pharmacology, pp.33-38, 1988.

G. Bacci, S. Ferrari, P. Picci, C. Zolezzi, F. Gherlinzoni et al., Methotrexate Serum Concentration and Histological Response to Multiagent Primary Chemotherapy for Osteosarcoma of the Limbs, Journal of Chemotherapy. janv, vol.8, issue.6, pp.472-480, 1996.

G. Bacci, L. Loro, A. Longhi, F. Bertoni, P. Bacchini et al., No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma: AntiCancer Drugs, avr, vol.17, issue.4, pp.411-416, 2006.

S. Zelcer, M. Kellick, L. H. Wexler, W. Shi, M. Sankaran et al., Methotrexate levels and outcome in osteosarcoma, Pediatric Blood & Cancer. 15 juin, vol.44, issue.7, pp.638-680, 2005.

F. Lin, Y. Juan, S. Zheng, Z. Shen, L. Tang et al., Relationship of serum methotrexate concentration in high-dose methotrexate chemotherapy to prognosis and tolerability: A prospective cohort study in chinese adults with osteosarcoma, Current Therapeutic Research. avr, vol.70, issue.2, pp.150-60, 2009.

B. Wang, H. Yao, X. Xie, J. Yin, C. Zou et al., Relationship of peak serum methotrexate concentration to prognosis and drug tolerance in non-metastatic extremity osteosarcomas, Cancer Chemotherapy and Pharmacology. août, vol.82, issue.2, pp.221-228, 2018.

A. Ferreri, E. Guerra, M. Regazzi, F. Pasini, A. Ambrosetti et al., Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas, British Journal of Cancer. janv, vol.90, issue.2, pp.353-361, 2004.

M. Joerger, A. Huitema, S. Krähenbühl, J. Schellens, T. Cerny et al., Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial, British Journal of Cancer. févr, vol.102, issue.4, pp.673-680, 2010.

H. Blasco, D. Senecal, L. Gouge, A. Pinard, E. Benz-de-bretagne et al., Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma: Methotrexate exposure in patients treated with MBVP chemotherapy, British Journal of Clinical Pharmacology. sept, vol.70, issue.3, pp.367-75, 2010.

B. Kasenda, M. Rehberg, P. Thürmann, M. Franzem, H. Veelken et al., The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients, Annals of Hematology. août, vol.91, issue.8, pp.1257-64, 2012.

S. Dalia, S. Price, P. Forsyth, L. Sokol, and M. Jaglal, What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?, Leukemia & Lymphoma. févr, vol.56, issue.2, pp.500-502, 2015.

J. Farhi, K. Laribi, C. Orvain, J. Hamel, M. Mercier et al., Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma, Annals of Hematology. déc, vol.97, issue.12, pp.2391-401, 2018.

W. Woessmann, K. Seidemann, G. Mann, M. Zimmermann, B. Burkhardt et al., The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with Bcell neoplasms: a report of the BFM Group Study NHL-BFM95, Blood. 1 févr, vol.105, issue.3, pp.948-58, 2005.

T. S. Mikkelsen, A. Sparreboom, C. Cheng, Y. Zhou, J. M. Boyett et al., Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial, Journal of Clinical Oncology. mai, vol.29, issue.13, pp.1771-1779, 2011.

A. Wall, A. Gajjar, A. Link, H. Mahmoud, C. Pui et al., Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia, Leukemia. févr, vol.14, issue.2, pp.221-226, 2000.

J. H. Foster, P. A. Thompson, M. B. Bernhardt, J. F. Margolin, S. G. Hilsenbeck et al., A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities, Cancer Chemotherapy and Pharmacology, pp.1-12, 2018.

, Methotrexate : Résumé des Caractéristiques du Produit -Food and Drug Administration

T. S. Mikkelsen, A. D. Mamoudou, R. Tuckuviene, P. S. Wehner, and H. Schroeder, Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: A prospectively randomized cross-over study: Prehydration for High-Dose Methotrexate, Pediatric Blood & Cancer. févr, vol.61, issue.2, pp.297-301, 2014.

O. Mir, S. Ropert, A. Babinet, J. Alexandre, F. Larousserie et al., Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma, Cancer Chemotherapy and Pharmacology, vol.66, issue.6, pp.1059-63, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00568280

S. C. Howard, J. Mccormick, C. Pui, R. K. Buddington, and R. D. Harvey, Preventing and Managing Toxicities of High-Dose Methotrexate, The Oncologist. 1 déc, vol.21, issue.12, pp.1471-82, 2016.

, Groupe Lymphomes Oculo-Cérébraux. Recommandations pour le traitement des lymphomes oculaires et cérébraux, 2014.

F. De and . Iv,

L. De and . Iv,

, Folinate de calcium per os : Résumé des Caractéristiques du Produit -Base de données publique des médicaments

D. M. Boarman, J. Baram, and C. J. Allegra, Mechanism of leucovorin reversal of methotrexate cytotoxicity in human MCF-7 breast cancer cells, Biochemical Pharmacology. déc, vol.40, issue.12, pp.2651-60, 1990.

L. B. Ramsey, F. M. Balis, M. M. O'brien, K. Schmiegelow, J. L. Pauley et al., Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. The Oncologist, vol.23, pp.52-61, 2017.

S. Tvc, H. Anderson, J. Heldrup, J. Kanerva, H. Seidel et al., High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia, Leukemia. 21 sept, issue.20, pp.1955-62, 2006.

F. Albertioni, C. Rask, S. Eksborg, J. H. Poulsen, B. Pettersson et al., Evaluation of clinical assays for measuring high-dose methotrexate in plasma, Clinical Chemistry, vol.42, issue.1, pp.39-44, 1996.

C. Piard, F. Bressolle, M. Fakhoury, D. Zhang, K. Yacouben et al., A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia, Cancer Chemotherapy and Pharmacology. 17 juill, vol.60, issue.4, pp.609-629, 2007.

N. Pottier, Pharmacogénomique des anticancéreux : exemples de la Bléomycine et du Méthotrexate, 2010.

A. Ongaro, M. De-mattei, D. Porta, M. G. Rigolin, G. et al., Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival, Haematologica, vol.94, issue.10, pp.1391-1399, 2009.

V. D'angelo, M. Ramaglia, A. Iannotta, S. Crisci, P. Indolfi et al., Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants, Cancer Chemotherapy and Pharmacology, vol.68, issue.5, pp.1339-1385, 2011.

N. M. El-khodary, S. M. El-haggar, M. A. Eid, and E. N. Ebeid, Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia, Medical Oncology. sept, vol.29, issue.3, pp.2053-62, 2012.

P. Chiusolo, S. Giammarco, S. Bellesi, E. Metafuni, N. Piccirillo et al., The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue, Cancer Chemotherapy and Pharmacology. mars, vol.69, issue.3, pp.691-697, 2012.

S. Dulucq, G. St-onge, V. Gagne, M. Ansari, D. Sinnett et al., DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL, Blood. 1 avr, vol.111, issue.7, pp.3692-700, 2008.

L. R. Treviño, N. Shimasaki, W. Yang, J. C. Panetta, C. Cheng et al., Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects, Journal of Clinical Oncology. 10 déc, vol.27, issue.35, pp.5972-5980, 2009.

L. B. Ramsey, J. C. Panetta, C. Smith, Y. W. Fan, Y. Winick et al., Genome-wide study of methotrexate clearance replicates SLCO1B1, Blood. 7 févr, vol.121, issue.6, pp.898-904, 2013.

M. Kienana, I. Benz-de-bretagne, L. Nadal-desbarats, H. Blasco, E. Gyan et al., Endogenous metabolites that are substrates of organic anion transporter's (OATs) predict methotrexate clearance, Pharmacological Research. avr, vol.118, pp.121-153, 2017.

R. Gorlick, E. Goker, T. Trippett, M. Waltham, D. Banerjee et al., Intrinsic and Acquired Resistance to Methotrexate in Acute Leukemia, New England Journal of Medicine, vol.335, issue.14, pp.1041-1049, 1996.

E. L. Volk and E. Schneider, Wild-Type Breast Cancer Resistance Protein (BCRP/ABCG2) is a Methotrexate Polyglutamate Transporter, Cancer Research. 1 sept, vol.63, pp.5538-5581, 2003.

J. R. Bertino, E. Göker, R. Gorlick, W. W. Li, and D. Banerjee, Resistance Mechanisms to Methotrexate in Tumors, Stem Cells. janv, vol.14, issue.1, pp.5-9, 1996.

L. Holmboe, A. M. Andersen, L. Mørkrid, L. Slørdal, and K. S. Hall, High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients: High dose methotrexate toxicity in osteosarcoma patients, British Journal of Clinical Pharmacology. janv, vol.73, issue.1, pp.106-120, 2012.

K. Jahnke, A. Korfel, P. Martus, M. Weller, U. Herrlinger et al., High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma, Annals of Oncology. 1 mars, vol.16, issue.3, pp.445-454, 2005.

G. Bacci, S. Ferrari, A. Longhi, C. Forni, L. Loro et al., Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy, Oncology Reports, vol.10, issue.4, pp.251-258, 2003.

T. Skärby, P. Jönsson, L. Hjorth, M. Behrentz, O. Björk et al., High-dose methotrexate : on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL), Cancer Chemotherapy and Pharmacology. 28 mars, issue.51, pp.311-331, 2003.

Y. Kagawa, R. Mukohara, H. Hori, H. Kawasaki, Y. Komada et al., Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy, Cancer Chemotherapy and Pharmacology. juill, vol.54, issue.1, pp.34-42, 2004.

S. Schwartz, K. Borner, K. Muller, P. Martus, L. Fischer et al., Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients with Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy. The Oncologist, vol.12, pp.1299-308, 2007.

F. Ranchon, N. Vantard, E. Henin, E. Bachy, C. Sarkozy et al., Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences? Hematological Oncology, vol.36, pp.399-406, 2017.

R. G. Stoller, K. R. Hande, S. A. Jacobs, S. A. Rosenberg, and B. A. Chabner, Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity, New England Journal of Medicine, vol.297, issue.12, pp.630-634, 1977.

M. V. Relling, D. Fairclough, D. Ayers, W. R. Crom, J. H. Rodman et al., Patient characteristics associated with high-risk methotrexate concentrations and toxicity, Journal of Clinical Oncology. août, vol.12, issue.8, pp.1667-72, 1994.

W. Xu, Y. Tang, H. Song, S. Shi, and S. Yang, Retrospective Study on Elimination Delay of Methotrexate in High-dose Therapy of Childhood Acute Lymphoblastic Leukemia in China: Journal of Pediatric Hematology/Oncology, vol.29, pp.688-93, 2007.

K. Cheng, Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer, European Journal of Cancer Care. mai, vol.17, issue.3, pp.306-317, 2008.

S. T. Sonis, The pathobiology of mucositis, Nature Reviews Cancer. avr, vol.4, issue.4, pp.277-84, 2004.

J. Mao, L. Zhang, H. Shen, Y. Tang, H. Song et al., Creatinine clearance rate and serum creatinine concentration are related to delayed methotrexate elimination in children with lymphoblastic malignancies, Neoplasma, vol.61, issue.01, pp.77-82, 2014.

S. Yang, F. Zhao, H. Song, D. Shen, and X. Xu, Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate, The Scientific World Journal, vol.2015, pp.1-8, 2015.

M. Tsurusawa, M. Gosho, T. Mori, T. Mitsui, S. Sunami et al., Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma: HDMTX and Toxicity in Childhood B-NHL, Pediatric Blood & Cancer. févr, vol.62, issue.2, pp.279-84, 2015.

Y. Yang, X. Wang, J. Tian, and Z. Wang, Renal Function and Plasma Methotrexate Concentrations Predict Toxicities in Adults Receiving High-Dose Methotrexate, Medical Science Monitor, vol.2018, issue.24, pp.7719-7745, 2018.

D. Feinsilber, R. J. Leoni, D. Siripala, J. Leuck, and K. A. Mears, Evaluation, Identification, and Management of Acute Methotrexate Toxicity in High-dose Methotrexate Administration in Hematologic Malignancies, Cureus. 8 janv, vol.10, issue.1, pp.1-8, 2018.

L. Hempel, J. Misselwitz, C. Fleck, K. Kentouche, C. Leder et al., Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function, Medical and Pediatric Oncology. juin, vol.40, issue.6, pp.348-54, 2003.

B. C. Widemann, F. M. Balis, B. Kempf-bielack, S. Bielack, C. B. Pratt et al., High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: Incidence, treatment, and outcome, Cancer. 15 mai, vol.100, issue.10, pp.2222-2254, 2004.

M. R. Green and M. C. Chamberlain, Renal dysfunction during and after high-dose methotrexate, Cancer Chemotherapy and Pharmacology. mars, vol.63, issue.4, pp.599-604, 2009.

J. May, K. R. Carson, S. Butler, W. Liu, N. L. Bartlett et al., High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis, Leukemia & Lymphoma. juin, vol.55, issue.6, pp.1345-1354, 2014.

A. P. Garneau, J. Riopel, and P. Isenring, Acute Methotrexate-Induced Crystal Nephropathy, New England Journal of Medicine. 31 déc, vol.373, issue.27, pp.2691-2694, 2015.

W. Zhang, Q. Zhang, T. Zheng, J. Zhen, and X. Niu, Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients, Chinese Medical Journal, vol.129, issue.21, pp.2530-2534, 2016.

T. Wiczer, E. Dotson, A. Tuten, G. Phillips, and K. Maddocks, Evaluation of incidence and risk factors for highdose methotrexate-induced nephrotoxicity, Journal of Oncology Pharmacy Practice. juin, vol.22, issue.3, pp.430-436, 2016.

D. Cheng, H. Lu, T. Liu, X. Zou, and H. Pang, Identification of Risk Factors in High-Dose Methotrexate-Induced Acute Kidney Injury in Childhood Acute Lymphoblastic Leukemia, Chemotherapy. 19 avr, vol.63, issue.2, pp.100-106, 2018.

H. T. Abelson, M. T. Fosburg, G. P. Beardsley, A. M. Goorin, C. Gorka et al., Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine, Journal of Clinical Oncology. mars, vol.1, issue.3, pp.208-224, 1983.

C. D. Flombaum, D. Liu, S. Q. Yan, A. Chan, S. Mathew et al., Management of Patients with Acute Methotrexate Nephrotoxicity with High-Dose Leucovorin, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. juill, vol.38, issue.7, pp.714-738, 2018.

A. S. Krause, M. R. Weihrauch, U. Bode, G. Fleischhack, T. Elter et al., Carboxypeptidase-G 2 Rescue in Cancer Patients with Delayed Methotrexate Elimination after High-dose Methotrexate Therapy, Leukemia & Lymphoma. janv, vol.43, issue.11, pp.2139-2182, 2002.

S. Buchen, D. Ngampolo, R. G. Melton, C. Hasan, A. Zoubek et al., Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure, British Journal of Cancer. févr, vol.92, issue.3, pp.480-487, 2005.

J. Green, Glucarpidase to combat toxic levels of methotrexate in patients. Therapeutics and Clinical Risk Management, pp.403-416, 2012.

R. F. Sherwood, R. G. Melton, S. M. Alwan, and P. Hughes, Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method, European Journal of Biochemistry. mai, vol.148, issue.3, pp.447-53, 1985.

G. Hempel, R. Lingg, and J. Boos, Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications, Cancer Chemotherapy and Pharmacology. avr, vol.55, issue.4, pp.347-53, 2005.

B. Widemann, E. Sung, L. Anderson, W. Salzer, F. Balis et al., Pharmacokinetics and metabolism of the methotreaxte metabolite 2, 4-diamino-N(10)-methylpteroic acid, Journal of Pharmacology and Experimental Therapeutics. sept, vol.294, issue.3, pp.894-901, 2000.

, Voraxaze : Résumé des Caractéristiques du Produit -Food and Drug Administration

B. C. Widemann, Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction, Pediatric Blood & Cancer. sept, vol.62, issue.9, pp.1512-1515, 2015.

B. C. Widemann, F. M. Balis, A. Kim, M. Boron, N. Jayaprakash et al., Leucovorin, and Thymidine for High-Dose Methotrexate-Induced Renal Dysfunction: Clinical and Pharmacologic Factors Affecting Outcome, Journal of Clinical Oncology. sept, vol.28, issue.25, pp.3979-86, 2010.

B. C. Widemann, S. Schwartz, N. Jayaprakash, R. Christensen, C. Pui et al., Efficacy of Glucarpidase (Carboxypeptidase G2) in Patients with Acute Kidney Injury After High-Dose Methotrexate Therapy, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. mai, vol.34, issue.5, pp.427-466, 2014.

H. Blasco, S. Silly, J. Tournamille, E. Gyan, D. Sénécal et al., Les critères d'utilisation de la carboxypeptidase dans les surexpositions au méthotrexate doivent être mieux définis, Thérapie. janv, vol.63, issue.1, pp.19-28, 2008.

. Omedit-centre, Fiche de recommandations : Carboxypeptidase G2 et surdosage en méthotrexate, 2008.

J. J. Griggs, P. B. Mangu, H. Anderson, E. P. Balaban, J. J. Dignam et al., Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer, Clinical Oncology Clinical Practice Guideline. JOURNAL OF CLINICAL ONCOLOGY. 1 mai, vol.30, issue.13, pp.1553-61, 2012.

M. El-sanharawi and F. Naudet, Comprendre la régression logistique, Journal Français d'Ophtalmologie. oct, vol.36, issue.8, pp.710-715, 2013.